WHO ICTRP trial
Phase 2 open-label study of MIV-210 in antiretroviral treatment experienced…
EUCTR2005-001738-34-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-001738-34-GB |
|---|---|
| Public title | Phase 2 open-label study of MIV-210 in antiretroviral treatment experienced HIV-1 infected subjects |
| Scientific title | Phase 2 open-label study of MIV-210 in antiretroviral treatment experienced HIV-1 infected subjects |
| Primary sponsor | Medivir AB |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United Kingdom |
| Conditions | HIV-1 infection |
| Interventions | Product Name: MIV-210 Pharmaceutical Form: Capsule, hard Current Sponsor code: MIV-210 hemisulphate salt Other descriptive name: MSS-157, GSK204937A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- |
| Registration date | May 27, 2005 |
| Target size | 12 |
| Secondary IDs | 210-03 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: